Executive Leadership Team

Rooted in science and technology, we are building our team from the ground up to be interdisciplinary at the core.

Ali Ansary, MD

CEO & Co-Founder

Ali is a physician fascinated by finding answers to the unknown. Prior to founding Ozette, he served as a consultant for McKinsey & Company and advisor to startups and venture capital firms. Ali completed his medical training at the University of Washington, where he continues to hold a part-time clinical appointment with the Fred Hutchinson Cancer Center. He has cultivated his curiosity into a lifelong passion for helping to deliver high quality science and medicine to the patients he serves.

Arthur Maloy

Chief Financial Officer

Arthur is an experienced operator and investor who has served in senior management roles and led investments in a wide variety of companies. He is passionate about new applications for innovative technology. Prior to Ozette, Arthur was CFO for Turing AI, CFO/COO for the investment firm Ascent Capital Advisors, and previously worked at the investment banks Goldman Sachs, Nomura and Lehman Brothers. Arthur is a graduate of the Wharton School of the University of Pennsylvania.

Ashley Wilson, PhD

Head of Immunology

Ashley is an immunologist with deep expertise in progressing novel cellular immunotherapies into clinical trials. She has a passion for translating science from bench to bedside and back again. Prior to Ozette, Ashley was Director of Therapeutics Correlative Science at Seattle Children’s Therapeutics, where she worked closely with a leading CAR T therapy team launching next-generation cell and gene therapy trials for children and young adults. She earned her PhD in microbiology, immunology and cancer biology from the University of Virginia before continuing on as a postdoctoral fellow studying CD8+ T cell infiltration and checkpoint blockade immunotherapy within the context of solid tumors.

Catherine Sanders

VP, Business Development

Catherine is an immunopathologist with more than 15 years of experience in immunosequencing and immune profiling. Prior to joining Ozette, Catherine served as Vice President of Research and Business Development at Adaptive Biotechnologies Corp. where she was responsible for establishing partnerships with pharmaceutical companies and key opinion leaders in academia to drive drug discovery and therapeutic development in oncology, hematology, infectious disease, and autoimmunity. Catherine holds a Ph.D. in immunopathology from University of Mississippi Medical Center, an M.S. in pathology from University of Mississippi, and a B.S. in medical technology from Mississippi State University.

Greg Finak, PhD

CTO & Co-Founder

Greg is a recognized leader and pioneer in the field of computational cytometry and single-cell methods development. He is passionate about technology and a champion for  rigorous, high quality, reproducible and open science. He founded Ozette in 2020 with the guiding principle that scientific questions should push technology development. Prior to founding Ozette he served as a Senior Scientist at the Fred Hutchinson Cancer Research Center where he contributed to methods development and analysis of vaccine clinical trial data across HIV, TB, Malaria, and other disease areas. He graduated with a PhD from McGill University.

Fritz Lekschas, PhD

Head of Visualization Research

Fritz is a computer scientist advancing the frontiers of scalable visual exploration of biomedical data. As the Head of Visualization Research at Ozette, he is leading the development of web-based data visualization and exploration tools for analyzing high-dimensional single-cell datasets. Fritz has published more than twenty peer-reviewed papers in renowned journals and computer science conferences, including Nature and Bioinformatics, and won several prestigious awards from the visualization research community. Fritz earned his PhD in computer science from Harvard University where he worked under the supervision of Hanspeter Pfister and Nils Gehlenborg on scalable visualization tools for pattern-driven data exploration.

Evan Greene, PhD

Chief Data Science Research Officer & Co-Founder

Evan is a globally recognized statistician pioneering new methods for the analysis of single-cell immune data. Prior to founding Ozette, he was a postdoctoral scholar and then data scientist at the Fred Hutchinson Cancer Center. In those roles, he worked on methods development for data generated by high-throughput single-cell instruments, and analyzed data generated by such instruments. Evan completed his PhD in statistics at the University of Washington.

Raphael Gottardo, PhD

Scientific Advisor & Co-Founder

Raphael is a pioneer of novel computational tools and methods to address today’s most pressing immunological problems through high-dimensional modeling and data integration. In 2018, he received the Mortimer Spiegelman Award, which honors a statistician below the age of 40 who has made outstanding contributions to health statistics. Raphael is a Full Professor of Biomedical Data Science at the University of Lausanne and the founding director of the Biomedical Data Science Center at the University Hospital of Lausanne. Before that, he was a Full Professor in the Vaccine and Infectious Disease Division at Fred Hutchinson Cancer Center, an affiliate Professor of statistics at the University of Washington, and scientific director of the Fred Hutch Translational Data Science Integrated Research Center. Dr. Gottardo’s current research interests center on the development of computational tools and new machine learning methods for analyzing high-dimensional single-cell data with applications to immunology, vaccine research, and immunotherapy. He has led a large number of projects funded by the National Institutes of Health, the Gates Foundation, and the Chan-Zuckerberg Initiative, among others.

Cherie Green

VP Translational Science

Cherie is an established member and thought-leader of the cytometry community, where she’s driven impact for more than 25 years focusing on hematopathology, cell therapy, and biotech biomarker laboratories. As a biomarker scientist, her professional focus lies in understanding cellular interactions in complex diseases and the development of novel therapies. She is passionate about development of innovative single assays and computational analysis solutions to advance life changing therapeutic development. During her tenure at Amgen, Genentech, and small cell therapy companies, she championed the design and use of biomarkers in clinical trial design for early and late stage drug development in infectious, autoimmune, and oncology diseases. She has served as the co-chair of Flow Cytometry Action Committee of the American Association of Pharmaceutical Scientists (AAPS) and has co-authored over 50 publications and patents on topics specific to drug development such as instrument and assay validation, sample stability, and receptor occupancy, and biomarkers.

Corrie Ortega, PhD

VP Operations & Product Strategy

Corrie is most passionate about innovative health technologies which deliver impactful solutions for better patient outcomes. For more than 15 years, she has translated research into healthcare products. Prior to Ozette, Corrie led part of the health technologies portfolio at Global Health Labs, scaling and leading teams to take products from concept to delivery. She earned her PhD from the Department of Global Health at the University of Washington and a BA from the Department of Public Health at Johns Hopkins University.


Bill Glauser, PhD

SVP, XtalPi

Bill is the Head of Strategy at XtalPi, Inc., where he leverages two decades of experience applying physics-based in silico solutions to critical problems in discovery and development. Prior to that, he was Vice President of Strategic Business at Schrodinger, LLC, a leader in predictive software modeling and drug discovery services. Bill held a postdoctoral fellowship at the University of California, Berkeley in theoretical chemistry after earning a Ph.D. from the University of South Florida in computational chemistry. He then earned an MBA in Technology Evaluation and Commercialization from North Carolina State University, where he co-founded an AI-driven company specializing in bioprocessing

Charlotte Hubbard, PhD

Sr Director, Nanostring

Dr. Charlotte Hubbert is Senior Director, Business Development & Strategic Alliances at NanoString and Strategic Director at Madrona Venture Group. Charlotte was previously Partner and head of Gates Foundation Venture Capital and Vice President at H.I.G. BioVentures.  Charlotte career began in early stage biotech, investing at Accelerator Corporation. Charlotte holds a B.S. in microbiology from the University of Washington and a Ph.D from Duke University. She has been honored as a Fierce Woman in Biopharma 2016 by Fierce Pharma, and as a leading Woman in Life Sciences 2016 by Life Science Washington.

Lennie Sender, MD

COO, ImmunityBio

Dr. Lennie Sender joined ImmunityBio in March 2020 as Chief Operating Officer, having previously served as Senior Vice President of Medical Affairs at NantKwest. He formerly worked as the Medical Director of the Hyundai Cancer Institute at Children’s Hospital in Orange County, California, and as the Medical Director of Clinical Oncology at theUniversity of California’s National Cancer Institute-designated Chao Family Comprehensive Cancer Center. Dr. Sender is a skilled transplant surgeon who earned his medical degree from the University of the Witwatersrand in Johannesburg, South Africa, and then went on to study pediatrics at the University of California, Irvine, and pediatric hematology-oncology at Children’s Hospital Los Angeles. He was formerly President of the Society for Adolescent and Young Adult Oncology and Editor-in-Chief of the Journal of Adolescent and Young Adult Oncology.

Robert Hershberg, MD, PhD

Board Member, Adaptive, Nanostring, Fate Therapeutics

Rob is a venture partner on the Frazier Life Sciences team. He co-founded and currently serves as the Chairman of the Board and Chief Executive Officer of HilleVax. Rob previously served in several roles at VentiRx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, which he co-founded in 2006, and was Chief Executive Officer from 2012 until the company’s acquisition by Celgene in February 2017. Rob holds multiple board seats and serves as a clinical faculty member at the University of Washington School of Medicine. He holds a PhD in Biology from University of California, San Diego’s Affiliated PhD Program with the Salk Institute for Biological Studies and an MD and a BA from the University of California, Los Angeles.

Ryan Panchadsaram

Partner, Kleiner Perkins

Ryan focuses on venture-stage companies and serves as technical advisor to John Doerr, Chair of Kleiner Perkins. Ryan was the Deputy Chief Technology Officer for the United States where he helped shape how an $80 billion budget should be used by federal agencies, served as part of the crisis response team that rescued the rollout of Healthcare.gov, helped launch the U.S. Digital Service, and was a US delegate to the United Nations. Prior to public service, Ryan co-founded Pipette, a digital health startup that was acquired by Ginger.io, and worked at Microsoft and Salesforce.com in product and engineering roles. Ryan graduated with a degree in Industrial Engineering and Operations Research from the University of California, Berkeley.